Home/Pipeline/RGFields for HIV

RGFields for HIV

HIV

Clinical (phase unspecified)Active

Key Facts

Indication

HIV

Phase

Clinical (phase unspecified)

Status

Active

Company

Anapole Technologies

About Anapole Technologies

Anapole Technologies is a private, pre-revenue medical device and drug delivery company commercializing a novel, non-invasive therapeutic platform based on Resonance Generating Fields (RGFields). The technology has shown clinical effectiveness against HIV and pre-clinical success in tuberculosis and certain cancers, positioning it as a potential paradigm shift in treatment modalities. Led by an experienced team with strong financial and military backgrounds, the company is seeking strategic partners to bring its cost-effective, scalable system to market. Its value proposition centers on high ROI for providers and broader patient access due to lower treatment costs and backward-compatible hardware upgrades.

View full company profile

Therapeutic Areas

Oncology Infectious Disease

Other HIV Drugs

Drug	Company	Phase	Status
Vaxine HIV Vaccine	Vaxine	Preclinical	Active
OraQuick® HIV Self-Test	OraSure	Commercial	FDA Approved; Marketed
Tenofovir Disoproxil Fumarate	Hetero	Commercial	Active
NanoDDI	Continuity Biosciences	Pre-clinical	Active
HIV Gene Therapy	Nanite	Pre-clinical	Active
HIV mAb Program	Adnexus	Pre-clinical	Active
Undisclosed Program	EnnoDC	Phase 1	Active
O2-16 Series	OyaGen	Preclinical	Active
SBX 2048	Stramsen Biotech	Early-stage Clinical	Active
ALF Platform	Senzo	Pre-clinical	Active
Gilead HIV Franchise	Royalty Pharma	Marketed	Active
ANKTIVA-based regimens	ImmunityBio	Phase 1/2	Active